Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy

Article Oncology

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K. Hansen et al.

Summary: A retrospective analysis showed that the safety and efficacy of standard-of-care ide-cel therapy in RRMM patients were similar to those seen in the phase II KarMMa trial, despite most patients not meeting the trial eligibility criteria.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin et al.

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Health Care Sciences & Services

Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

Amrita Krishnan et al.

Summary: The effectiveness of teclistamab was compared with real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. The results showed that teclistamab treated patients had significantly better overall survival, progression-free survival, and time to next treatment compared to the RWPC cohort. Therefore, it can be concluded that teclistamab offers clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2023)

Add to Collection

Review Oncology

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma

Aurelia Chacon et al.

Summary: The treatment of multiple myeloma (MM) has drastically improved over the years, especially for elderly patients. Chemotherapy was the main treatment for MM in the past, but targeted therapies such as immunomodulating agents and proteasome inhibitors have led to increased survival rates. The introduction of monoclonal antibodies has been a significant advancement in MM treatment for both transplant-eligible and non-transplant-eligible patients. However, further progress is expected with the use of innovative immunotherapy-based treatments like CAR-T cells and bispecific antibodies.

CANCERS (2023)

Add to Collection

Editorial Material Hematology

Melflufen for multiple myeloma: a promise unfulfilled?

Prashant Kapoor et al.

LANCET HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations

Amelie Boquoi et al.

Summary: Randomized controlled trials (RCT) play a crucial role in therapeutic innovations. However, the low participation rate of adult cancer patients in clinical trials, despite their willingness to participate, has been a challenge. This retrospective analysis of multiple myeloma patients found that the eligibility and consent rate for participation varied significantly between newly diagnosed and relapsed/refractory patients. The analysis suggests that addressing patient expectations and priorities could be a promising approach to increase enrollment in clinical trials.

CANCERS (2022)

Add to Collection

Article Oncology

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Jordan Nunnelee et al.

Summary: A retrospective study conducted at the Ohio State University showed that the survival rates and treatment responses of newly diagnosed multiple myeloma patients have significantly improved since 1992. This improvement can be attributed to the inclusion of novel therapies and post-autologous stem cell transplant maintenance. These findings underscore the importance of building on prior successes and continuing to develop new interventions.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody

Ajai Chari et al.

Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma

Tahani Atieh et al.

Summary: Outcomes in relapsed refractory myeloma remain poor, and novel therapy approaches are needed. This retrospective review analyzed the clinical outcomes of the combination of belantamab mafadotin and dexamethasone in heavily pretreated relapsed refractory myeloma patients, including those previously exposed to BCMA-targeted therapy. The results demonstrated the activity of this combination and supported further research on belantamab mafadotin in combination with other anti-myeloma therapies in this patient population.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Add to Collection

Article Oncology

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Rossella Iula et al.

Summary: Belantamab-mafodotin demonstrates efficacy and safety in treating multi-refractory/relapsed multiple myeloma patients, even in a real-world setting. The most common adverse event observed is keratopathy, but only a small percentage of patients need to discontinue treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau et al.

Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Anita D'Souza et al.

Summary: ABBV-383 demonstrates good tolerability and potential antitumor activity in patients with RRMM.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

GPRC5D-Targeted CAR T Cells for Myeloma

Sham Mailankody et al.

Summary: The study demonstrates that GPRC5D is an active immunotherapeutic target in multiple myeloma, and GPRC5D-targeted CAR T-cell therapy shows promising efficacy in heavily pretreated patients, including those who relapsed after BCMA CAR T-cell therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Meeting Abstract Hematology

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens

Luciano J. Costa et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Naresh Bumma et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman et al.

BLOOD (2022)

Add to Collection

Meeting Abstract Hematology

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Alexander M. Lesokhin et al.

BLOOD (2022)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Real-life data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience

I Vaxman et al.

Summary: Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma, showing promising results in clinical trials. However, it comes with side effects such as keratopathy, and the overall response rate is not high. Patients often receive multiple lines of therapy before using belantamab mafodotin, but the median progression-free survival and overall survival are relatively low.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Oncology

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

James Ackley et al.

Summary: Multiple myeloma is an incurable disease characterized by malignant plasma cells, making it a prime target for modern immune therapy. Immune therapy for multiple myeloma can be categorized into IMiDs, targeted antibodies, adoptive cell transfer therapies, and vaccines, all showing advancements in improving antitumor activity and specificity.

CANCERS (2021)

Add to Collection

Editorial Material Oncology

Myeloma: A Lot of Progress, Still a Long Way to Go

Gabor Mikala et al.

CANCERS (2021)

Add to Collection

Review Oncology

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma

Maarten R. Seefat et al.

Summary: New treatments for multiple myeloma can improve survival but come with higher costs, with cost-effectiveness ratios generally exceeding current willingness-to-pay thresholds. Access to promising treatments may require improved cost-effectiveness or acceptance of higher cost-effectiveness ratios.

CANCERS (2021)

Add to Collection

Review Oncology

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Massimo Martino et al.

Summary: Anti-BCMA CART-cell therapy has shown efficacy and manageable toxicity in heavily pretreated R/R MM patients. However, key issues such as patient relapse and safety concerns remain. Strategies to prevent relapse include dual-targeting CAR T-cells and upregulation of BCMA expression. The adverse effects of the therapy, such as CRS and neurologic toxicity, along with the extended manufacturing timeline and limited access to treatment, are important considerations for further development and optimization of BCMA-targeted CAR T-cell therapy.

CANCERS (2021)

Add to Collection

Review Oncology

Harnessing the Immune System to Fight Multiple Myeloma

Jakub Krejcik et al.

Summary: The treatment of multiple myeloma has advanced significantly in the last two decades, especially with the introduction of immunotherapies. Immune dysfunction is a key feature of multiple myeloma, prompting extensive research into treatment and prevention.

CANCERS (2021)

Add to Collection

Article Oncology